• Explore /
  • Poster
  • / LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Sumit Kumar Subudhi

The University of Texas MD Anderson Cancer Center, Houston, TX

Sumit Kumar Subudhi , Ralph J. Hauke , Justin A Call , Jichao Sun , Denise Casey , Xiao X. Wei

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05848011

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr TPS242)

DOI

10.1200/JCO.2024.42.4_suppl.TPS242

Abstract #

TPS242

Poster Bd #

Q3

Abstract Disclosures

Similar Posters

First Author: Benedito A. Carneiro

First Author: Dana E. Rathkopf

First Author: Simon J. Crabb

First Author: Mark N. Stein